The authors declare that they have no competing interests.
Article first published online: 14 SEP 2010
Copyright © 2010 Wiley-Liss, Inc.
Volume 71, Issue 3, pages 326–331, 15 February 2011
How to Cite
Zhang, H.-L., Yang, L.-F., Zhu, Y., Yao, X.-D., Zhang, S.-L., Dai, B., Zhu, Y.-P., Shen, Y.-J., Shi, G.-H. and Ye, D.-W. (2011), Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate, 71: 326–331. doi: 10.1002/pros.21246
Dingwei Ye conceived the study, supervised the experiments, prescribed the chemotherapy, analyzed the data and contributed in manuscript preparation. Hailiang Zhang and Lifeng Yang hold equal contribution to this article. Hailiang Zhang participated in the design of the study, qRT-PCR, review of related literatures and drafting the manuscript. Lifeng Yang contributed in qRT-PCR analyses, collection and analyses of the final data, and preparation of the manuscript. Yao Zhu performed the statistical analysis. The other authors of this article participated in the study design, serum sample collection, informed consent collection, data collection, chart review, and helped with the draft of the manuscript. All authors revised and approved the final manuscript.
- Issue published online: 20 JAN 2011
- Article first published online: 14 SEP 2010
- Manuscript Accepted: 12 JUL 2010
- Manuscript Received: 14 MAR 2010
- prostate cancer;
- hormone refractory;
- predictive factor
miR-21 has been recognized as an “onco-microRNA” with the activity of negatively modulating the expression of tumor-suppressor genes. However, its role in prostate cancer (CaP) has not been well-documented. We designed this study to assess the potential function of serum miR-21 in the progression of CaP.
Serum samples of 56 patients, including 20 patients with localized CaP, 20 with androgen-dependent prostate cancer (ADPC), 10 with hormone-refractory prostate cancer (HRPC), and 6 with benign prostatic hyperplasia (BPH), were collected for the measurement of miR-21. The 10 HRPC patients were administered docetaxel-based chemotherapy. Quantification of miR-21 was assayed by specific TaqMan qRT-PCR.
Serum miR-21 level was found to correlate to serum PSA level in patients with ADPC and HRPC, P = 0.012 and 0.049, respectively. There was no significant difference in serum miR-21 level between BPH, localized CaP and ADPC with PSA level <4 ng/ml. Higher levels of miR-21 were detected in patients with HRPC and ADPC with PSA level >4 ng/ml. Six of the 10 HRPC patients reached partial remission with a decreased PSA level of >50% after chemotherapy. Serum miR-21 levels were higher in patients who were resistant to docetaxel-based chemotherapy when compared to those sensitive to chemotherapy, P = 0.032.
Serum miR-21 levels are elevated in HRPC patients, especially in those resistant to docetaxel-based chemotherapy. It may be applicable as a marker to indicate the transformation to hormone refractory disease, and a potential predictor for the efficacy of docetaxel-based chemotherapy. Prostate 71:326–331, 2011. © 2010 Wiley-Liss, Inc.